- Record: found
- Abstract: found
- Article: not found
A Multicenter Analysis of Factors Associated With Apixaban-Related Bleeding in Hospitalized Patients With End-Stage Renal Disease on Hemodialysis.
Taylor D Steuber
1
,
2 ,
Dane L Shiltz
3
,
4 ,
Alex C Cairns
5
,
6 ,
Qian Ding
3 ,
Katie J Binger
5
,
6 ,
Julia R Courtney
5
,
6
Nov 2017
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In 2014, the United States Food and Drug Administration approved a labeling change for apixaban to include recommendations for patients with severe renal impairment and patients with end-stage renal disease (ESRD) on hemodialysis (HD), though these recommendations are largely based on pharmacokinetic and pharmacodynamic data.